Stockreport

UCB Canada remains dedicated to helping patients and working collaboratively with CDA-AMC following draft recommendation for (Pr)BIMZELX® for hidradenitis suppurativa (HS) [Yahoo! Finance]

UCB SA UNSP/ADR  (UCBJY) 
NASDAQ:AMEX Investor Relations: ucb.com/investors
PDF OAKVILLE, ON Jan. 21, 2026 /CNW/ - UCB Canada Inc. respectfully disagrees with the draft recommendation issued by the Canadian Drug Agency (CDA-AMC) regarding Pr BIMZEL [Read more]